Friday, 16 October 2026European Markets

ORDINA Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with ORDINA (ORDI.AS) rising 23.22% to €5.89 on Tuesday while AEX-Index jumped 0.98% to €736.18.

About ORDINA

Ordina N.V. provides IT services in the Netherlands, Belgium, and Luxembourg. It engages in the development and implementation of software solutions, as well as designing and managing IT landscapes. The company also provides consulting, technology, and outsourcing services. It serves customers in public, financial services, and industry sectors. Ordina N.V. was incorporated in 1973 and is headquartered in Nieuwegein, the Netherlands.

Earnings Per Share

As for profitability, ORDINA has a trailing twelve months EPS of €0.24.

PE Ratio

ORDINA has a trailing twelve months price to earnings ratio of 24.64. Meaning, the purchaser of the share is investing €24.64 for every euro of annual earnings.

Volume

Today's last reported volume for ORDINA is 12215100 which is 2449.79% above its average volume of 479064.

Volatility

ORDINA's last week, last month's, and last quarter's current intraday variation average was 4.09%, 1.10%, and 1.22%.

ORDINA's highest amplitude of average volatility was 4.09% (last week), 1.69% (last month), and 1.22% (last quarter).

More news about ORDINA (ORDI.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com